Plate Nº 52 · recorded November 17, 2026
Health & Medicine ResearchReported finding
Weekly CagriSema injection linked to 21% weight loss in 68-week trial
In a 68-week trial, adults staying on CagriSema lost about 21% of body weight on average, versus 2% with placebo. The mostly female trial cannot establish long-term benefit.
By Marcus Bennett3 min read586 words
In brief
- Published in November 2026, REDEFINE 9 followed 309 adults for 68 weeks at 24 centers in five countries.
- Among participants who stayed on treatment, average weight loss was 20.7% on the higher dose and 21.0% on the lower dose, versus 2.0% with the comparison injection.
- When all participants were counted, average losses were 19.4% on the higher dose, 18.6% on the lower dose and 4.6% in the comparison group.
- About half taking CagriSema lost at least 20% of their starting weight; waist size fell roughly 17 centimeters versus 4 centimeters in the comparison group.
- The trial was relatively small, mostly included women and did not establish long-term outcomes.

By Marcus Bennett
A 68-week trial found that adults who stayed on weekly CagriSema injections lost an average of 20.7% of their body weight on the higher dose and 21.0% on the lower dose, versus 2.0% with a placebo injection.
REDEFINE 9 tested the experimental weekly injection in 309 adults at 24 medical centers across five countries. The two dose levels produced similar weight loss, but CagriSema remains investigational.
What did the REDEFINE 9 trial test?
The study appeared in The Lancet Diabetes & Endocrinology in November 2026. Researchers followed the 309 adults for 68 weeks. Every participant had obesity or was overweight with a related health condition, and none had diabetes.
Participants were randomly assigned to three groups. Two received different dose levels of CagriSema, while the third received an injection without active medicine. Everyone also received advice about food and physical activity.
- Higher-dose CagriSema: average weight loss of 20.7% among participants who stayed on treatment.
- Lower-dose CagriSema: average weight loss of 21.0% among participants who stayed on treatment.
- Comparison injection: average weight loss of 2.0% among participants who stayed on treatment.
The lower dose did not produce a smaller average reduction than the higher dose in this trial. All three groups received lifestyle advice, so the results describe the injection when used alongside food and activity guidance.
What happened when researchers counted everyone?
Researchers also calculated results for all participants, including those who stopped treatment. Average weight loss reached 19.4% in the higher-dose group, 18.6% in the lower-dose group and 4.6% in the comparison group.
About half of the people taking CagriSema lost at least 20% of their starting weight. Their waist measurements fell by roughly 17 centimeters, compared with about 4 centimeters in the comparison group.
Including people who stopped treatment lowered the averages in both CagriSema groups, but substantial weight loss remained at either dose. For patients and prescribers, the main takeaway is that both tested dose levels showed substantial average weight loss.
How might CagriSema affect appetite?
CagriSema combines semaglutide and cagrilintide. Both medicines act on the body's signals for hunger and fullness, although they work in different ways. The goal is to help people feel satisfied with less food.
The similar results raise the possibility that doctors might one day select a dose according to a patient's needs, rather than assume that more medicine always produces better results.
That possibility still depends on confirmation in larger studies. For now, the lower dose performed as well as the higher dose on the trial's main weight measure.
Why does weight loss matter beyond body size?
Obesity can raise the risk of high blood pressure, heart disease and breathing problems during sleep. Losing weight can improve some of those health problems, though keeping weight off is often difficult.
REDEFINE 9 measured weight and waist size, not whether those health risks changed. It therefore supports the treatment's effect on those measurements, without establishing the full extent of its health benefits.
What remains uncertain?
This was a relatively small study, and its participants were mostly women. The results do not establish how well CagriSema works for everyone, or what happens after many years of treatment.
CagriSema remains an investigational treatment. Larger and longer studies need to confirm the findings before firm conclusions can be drawn. The weekly injection looks promising in this trial, but its average results should not be treated as a promise for an individual patient.
via knowridge.com (Source)
More from Marcus Bennett
Show full bio
News editor covering regulation, policy and their impact on general science news at SciBeat.
493 articles